MedTrace Logo

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

NCT00860158 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-03-14

Study results available
· View outcomes & findings →

Summary

This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.

Conditions

Interventions

DRUG

Dasatinib

Dasatinib 100 mg administered once daily per oral route for 28 consecutive days

DRUG

Leuprolide Acetate (LHRH Analogue)

Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).

PROCEDURE

Radical Prostatectomy

Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.

Sponsors & Collaborators

Principal Investigators

  • Noah Hahn, M.D. · Hoosier Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860158 on ClinicalTrials.gov